Unknown

Dataset Information

0

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.


ABSTRACT:

Background & aims

Antibodies against tumor necrosis factor-? are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD.

Methods

We conducted a retrospective cohort study by using U.S. Medicare data from 2006 through 2010. Patients with CD who were new users of infliximab (n = 1459) or adalimumab (n = 871) after January 31, 2007, were included. Patients older than age 85 and those with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis were excluded. The primary outcome measures were disease persistence on therapy at week 26, surgery (including bowel resection, creation of an ostomy, or surgical treatment of a perforation or abscess), and hospitalization for CD. Propensity score-adjusted logistic and Cox regression were used to compute adjusted odds ratios or hazard ratios and 95% confidence intervals (CIs).

Results

After 26 weeks of treatment, 49% of patients receiving infliximab remained on drug, compared with 47% of those receiving adalimumab (odds ratio, 0.98; 95% CI, 0.81-1.19). Fewer patients treated with infliximab underwent surgery than those treated with adalimumab, but this difference was not statistically significant (5.5 vs 6.9 surgeries per 100 person-years; hazard ratio, 0.79; 95% CI, 0.60-1.05). Rates of hospitalization did not differ between groups (hazard ratio, 0.88; 95% CI, 0.72-1.07).

Conclusions

We observed similar effectiveness of infliximab and adalimumab for CD on the basis of 3 clinically important outcome measures.

SUBMITTER: Osterman MT 

PROVIDER: S-EPMC3883891 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

Osterman Mark T MT   Haynes Kevin K   Delzell Elizabeth E   Zhang Jie J   Bewtra Meenakshi M   Brensinger Colleen C   Chen Lang L   Xie Fenlong F   Curtis Jeffrey R JR   Lewis James D JD  

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20130628 5


<h4>Background & aims</h4>Antibodies against tumor necrosis factor-α are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD.<h4>Methods</h4>We conducted a retrospective cohort study by using U.S. Medicare data from 2006 through 2010. Patients with CD who were new users of infliximab (n = 1459) or adalimumab (n = 871) after January 31, 2007, wer  ...[more]

Similar Datasets

| S-EPMC5881967 | biostudies-literature
| S-EPMC4917292 | biostudies-literature
| S-EPMC7737159 | biostudies-literature
| S-EPMC7263644 | biostudies-literature
| S-EPMC8762261 | biostudies-literature
| S-EPMC9132518 | biostudies-literature
| S-EPMC6701510 | biostudies-literature
| S-EPMC5083770 | biostudies-literature
| S-EPMC6375345 | biostudies-literature
| S-EPMC1954977 | biostudies-literature